1-Phenyl-propan-2.2.3-tricarbonsaeure-triethylester | 109554-51-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Phenyl-propan-2.2.3-tricarbonsaeure-triethylester
• 英文别名: 2-Benzyl-2-aethoxycarbonyl-bernsteinsaeure-diaethylester；3-phenyl-1,2,2-propanetricarboxylic acid 1,2,2-triethyl ester；3-phenyl-propane-1,2,2-tricarboxylic acid triethyl ester；3-Phenyl-propan-1,2,2-tricarbonsaeure-triaethylester；2-benzyl-2-carboxysuccinic acid triethyl ester；Triethyl 3-phenylpropane-1.2.2-tricarboxylate；Triethyl 3-phenyl-1,2,2-propanetricarboxylate；triethyl 1-benzylethane-1,1,2-tricarboxylate
• CAS: 109554-51-0
• 化学式: C₁₈H₂₄O₆
• 分子量: 336.385
• InChiKey: RPNRGCZUORVKJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-Phenyl-propan-2.2.3-tricarbonsaeure-triethylester 在 sodium hydroxide 、 乙醇 、 水 、 盐酸 作用下， 以 水 为溶剂， 反应 10.0h， 以82.6%的产率得到2-苄基丁二酸
  参考文献：
  名称：

  2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors

  摘要：

  提供了一些新的化合物，它们是糖原磷酸化酶抑制剂，可用于治疗、预防或减缓需要糖原磷酸化酶抑制剂治疗的疾病，如糖尿病及相关疾病（如高血糖、糖耐量受损、胰岛素抵抗和高胰岛素血症），与糖尿病相关的微血管并发症（如视网膜病变、神经病变、肾病和延迟伤口愈合），与糖尿病相关的大血管并发症（心血管疾病，如动脉粥样硬化、心脏功能异常、心肌缺血和中风），以及代谢综合征及其组成疾病，包括高血压、肥胖和脂质代谢异常（包括高三酸甘油酯血症、高胆固醇血症和低高密度脂蛋白血症），以及其他疾病，如非心脏缺血、感染和癌症。这些新的化合物具有特定的结构、立体异构体、前药或其药用可接受的盐，其中W、R1、R2、X和Z在此处有定义。

  公开号：

  US20060111338A1
• 作为产物：
  描述：

  丙二酸二乙酯钠盐 在 乙醇 、 sodium ethanolate 作用下， 生成 1-Phenyl-propan-2.2.3-tricarbonsaeure-triethylester
  参考文献：
  名称：

  Fittig; Roeders, Justus Liebigs Annalen der Chemie, 1890, vol. 256, p. 92

  摘要：

  DOI：

文献信息

• Therapeutic substituted indole compounds and compositions thereof
  申请人：Burroughs Wellcome Co.

  公开号：US05225431A1

  公开（公告）日：1993-07-06

  The present invention is concerned with compounds of formula (I) ##STR1## wherein R, R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl; R.sup.3 and R.sup.4 are independently selected from hydrogen, C.sub.1-6 alkyl (including cycloalkyl) and aryl (wherein the alkyl or aryl group, which latter includes benzyl, is optionally substituted by one or more atoms or groups independently selected from halogen, C.sub.1-4 alkyl and aryl), provided R.sup.3 benzyl or substituted benzyl when R.sup.4 =H; m is an integer of from 0 to 2; n is an integer of from 0 to 3; (W) is a group of formula (i), (ii), (iii), or (iv) ##STR2## wherein Y is selected from oxygen, methylene and >N--R.sup.5, where R.sup.5 is hydrogen, C.sub.1-4 alkyl, or benzyl, Z and Z' are independently selected from >C.dbd.O, >C.dbd.S and methylene, and the chiral center * in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions; X is a group selected from aryl (including heteroaryl) xanthenyl dibenzofuranyl which group is optionally substituted; and salts and solvates thereof, the preparation of these compounds, pharmaceutical formulations containing them and their use in medicine, particularly in the treatment of migraine.

  本发明涉及式(I)的化合物 其中R、R.sup.1和R.sup.2分别选自氢和C.sub.1-4烷基；R.sup.3和R.sup.4分别选自氢、C.sub.1-6烷基（包括环烷基）和芳基（其中烷基或芳基基团，后者包括苄基，可以选择地由一个或多个原子或基团独立选自卤素、C.sub.1-4烷基和芳基取代），只要R.sup.3苄基或取代苄基，当R.sup.4=H；m为0至2的整数；n为0至3的整数；(W)为式(i)、(ii)、(iii)或(iv)的基团 其中Y选自氧、亚甲基和>N--R.sup.5，其中R.sup.5为氢、C.sub.1-4烷基或苄基，Z和Z'分别选自>C.dbd.O、>C.dbd.S和亚甲基，式(i)或(ii)中的手性中心*为其(S)或(R)形式或它们的任意比例的混合物；X为选自芳基（包括杂环芳基）萘基二苯并呋喃基的基团，该基团可以选择地取代；以及它们的盐和溶剂化合物，这些化合物的制备，含有它们的药物制剂以及它们在医学中的使用，特别是在治疗偏头痛方面。
• Novel compounds
  申请人：SmithKline Beecham SpA

  公开号：US20040024218A1

  公开（公告）日：2004-02-05

  Compounds of formula I, or a salt thereof or a hydrate thereof, as follows: 1 wherein X and Y are selected independently from hydrogen and aryl, which aryl is unsubstituted or substituted one or more times by hydroxy, hydroxyC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, aryl, heterocyclyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, arylC 1-6 alkoxy, C 1-6 alkyl, C 1-6 alkoxy or halo, which alkyl or alkoxy groups are unsubstituted or substituted one or more times by halo; m and n are independently 0 to 3, provided that m and n are not both 0; A represents a single bond or is —(CR pa R pb ) p — wherein p is 1-3 and R pa and R pb are selected independently from hydrogen, C 1-6 alkyl, C 1-6 alkoxy and halo, which alkyl or alkoxy groups are independently substituted one or more times by halo; B represents a C 4-8 saturated or unsaturated ring, which ring is unsubstituted or substituted one or more times by C 1-6 alkyl, C 1-6 alkoxy, aryl, aryloxy, hydroxy, oxo, halo, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, and C 1-6 alkylamido, which C 1-6 alkyl or C 1-6 alkoxy groups are unsubstituted or substituted one or more times by halo, which aryl group is unsubstituted or substituted one or more times by aryl, heterocyclyl, aryloxy, arylC 1-6 alkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, arylC 1-6 alkyl, hydroxy, C 1-6 alkenoxy, C 1-6 alkoxy, halo, or C 1-6 alkyl, which C 1-6 alkyl may be substituted one or more times by halo, and which aryl group is linked to said ring by a single bond or is benzo-condensed therewith are ligands of the ORL-1 receptor.

  式I的化合物，或其盐或水合物，如下所示：其中X和Y分别选择自氢和芳基，所述芳基未取代或被羟基、羟基C1-6烷基、C1-6烷氧基C1-6烷基、芳基、杂环烷基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、芳基C1-6烷氧基、C1-6烷基、C1-6烷氧基或卤素取代一次或多次，其中烷基或烷氧基基团未取代或被卤素取代一次或多次；m和n独立地为0到3，但要求m和n不能同时为0；A代表单键或为—(CRpaRpb)p—，其中p为1-3且Rpa和Rpb独立选择自氢、C1-6烷基、C1-6烷氧基和卤素，其中烷基或烷氧基基团独立地被卤素取代一次或多次；B代表C4-8饱和或不饱和环，所述环未取代或被C1-6烷基、C1-6烷氧基、芳基、芳氧基、羟基、氧代、卤素、氨基、C1-6烷基氨基、二(C1-6烷基)氨基和C1-6烷酰胺取代一次或多次，其中C1-6烷基或C1-6烷氧基基团未取代或被卤素取代一次或多次，所述芳基未取代或被芳基、杂环烷基、芳氧基、芳基C1-6烷氧基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、芳基C1-6烷基、羟基、C1-6烯氧基、C1-6烷氧基、卤素或C1-6烷基取代一次或多次，所述C1-6烷基可能被卤素取代一次或多次，所述芳基通过单键与所述环相连或与之苯并结合的化合物是ORL-1受体的配体。
• Synthesis of optically active α-benzyl paraconic acids and their esters and assignment of their absolute configuration
  作者：Federico Berti、Cristina Forzato、Giada Furlan、Patrizia Nitti、Giuliana Pitacco、Ennio Valentin、Ennio Zangrando

  DOI：10.1016/j.tetasy.2009.01.027

  日期：2009.2

  their ethyl esters were synthesized with high enantiomeric excess by hydrolysis of the corresponding diastereomeric lactonic esters using α-chymotrypsin. Thus, at low conversion values, cis- and trans-4-benzyl-5-oxo-3-tetrahydrofurancarboxylic acids were separately isolated with 99% ee and 92% ee, respectively. Both ethyl ester diastereomers were also obtained in enantiopure form. The absolute configuration

  该顺式-和反式-4- benzylparaconic酸和它们的乙酯以高对映体过量通过使用α胰凝乳蛋白酶的非对映体相应的内酯的酯的水解合成。因此，在低转化率下，分别用99％ee和92％ee分离出顺式和反式-4-苄基-5-氧代-3-四氢呋喃羧酸。两种乙酯非对映异构体也都以对映纯形式获得。所述的绝对构型反式-lactonic酸通过分配1次及其酯衍生物的1 H NMR分析与1-（9-蒽基）-2,2,2-三氟乙醇两种对映体，而所述的顺通过结晶衍生物的X射线分析确定-内酯酸。还报告了所得产物的圆二色性曲线。
• Bischoff; Mintz, Chemische Berichte, 1890, vol. 23, p. 649
  作者：Bischoff、Mintz

  DOI：——

  日期：——
• Ramart-Lucas; Papadakis, Annales de Chimie (Cachan, France), 1932, vol. <10> 18, p. 32,48
  作者：Ramart-Lucas、Papadakis

  DOI：——

  日期：——